预约演示
更新于：2026-06-12
Romidepsin
罗米地辛
更新于：2026-06-12
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2009-11-05), |
最高研发阶段(中国)- |
特殊审评加速批准 (美国)、孤儿药 (美国)、孤儿药 (欧盟)、孤儿药 (日本) |
登录后查看时间轴
结构/序列
分子式C24H36N4O6S2 |
InChIKeyOHRURASPPZQGQM-GCCNXGTGSA-N |
CAS号128517-07-7 |
Sequence Code 525560087
关联
101
项与 罗米地辛 相关的临床试验NCT06963346
HERO Trial: Phase I Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents in Localized Bladder Cancer
NCT05230368
A Pilot Open Label Phase I Trial to Evaluate the Safety and the Tolerability of a Combination of Two HIV-1 Inducers in HIV+ Sub-type B Patients Under cART With Undetectable Viral Load
NCT04639843
A Phase 1 Study of Doxorubicin, CC-486 (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
100 项与 罗米地辛 相关的临床结果
登录后查看更多信息
100 项与 罗米地辛 相关的转化医学
登录后查看更多信息
100 项与 罗米地辛 相关的专利（医药）
登录后查看更多信息
1,294
项与 罗米地辛 相关的文献（医药）2026-08-01CLINICAL IMMUNOLOGY
Fc-enhanced anti-TIGIT antibody 30,278-IgG1 RMD amplifies antitumor immunity through effector cell activation and synergizes with PD-1 blockade
Article
作者: Lin, Yuanjie ; Yang, Limin ; Heng, Wei ; Zhang, Yu
TIGIT is an inhibitory immune checkpoint receptor, and its blockade has shown clinical promise in combination with PD-1 pathway inhibitors. However, whether anti-TIGIT antibodies should engage immune effector functions via Fcγ receptors (FcγRs) remains an open question. We developed 30,278-IgG1 RMD, a novel Fc-enhanced anti-TIGIT antibody, to amplify effector cell activation through FcγR engagement while preserving TIGIT binding and blockade. 30,278-IgG1 RMD was generated by Fc glycoengineering to increase affinity for activating FcγRs. This variant was compared to wild-type IgG1, an Fc-inert IgG4, and tiragolumab in in vitro assays (TIGIT binding/blockade, ADCC, ADCP, Treg depletion, immune cell activation in human PBMCs) and in an hTIGIT/hPD-1 knock-in mouse colon carcinoma model (CT26) combined with PD-1 blockade. 30,278-IgG1 RMD maintained high TIGIT affinity and blockade activity, while exhibiting markedly increased binding to activating FcγRs. It triggered more potent ADCC and ADCP than wild-type or tiragolumab, resulting in efficient depletion of TIGIT+ Tregs and activation of NK cells and dendritic cells. In human PBMC assays, the Fc-enhanced antibody augmented T cell activation and cytokine production relative to Fc-silent and wild-type controls. In vivo, 30278-IgG1 RMD plus PD-1 blockade yielded superior tumor control, including complete tumor regressions in some mice, whereas Fc-inert or wild-type anti-TIGIT combinations did not. Fc engineering of an anti-TIGIT antibody substantially improves immune effector engagement and anti-tumor efficacy. Augmenting FcγR interactions alongside checkpoint blockade can potentiate T cell responses and drive tumor regression, underscoring the translational potential of Fc-optimized checkpoint immunotherapies.
2026-08-01BIOORGANIC CHEMISTRY
Romidepsin inhibits NRF2 and enhances the efficacy of adagrasib by inducing autophagic cell death in KRAS-mutant tumor cells
Article
作者: Chen, Yunzhi ; Xia, Yiqun ; Shu, Chongchong ; Chen, Jundixia ; Jiang, Yiyan ; Zou, Peng ; Yang, Fan ; Ni, Daoyong ; Yan, Ying ; Fu, Wenying ; Tian, Fei ; Cui, Ri ; Chen, Xiao
KRAS-mutant tumors remain a major challenge in cancer therapy. Although current targeted drugs show initial promise, their efficacy is often limited by the development of resistance. Therefore, identifying effective drug combinations to target KRAS-mutant tumors is of great significance. This study investigates the synergistic potential of romidepsin (RO), a class I HDAC inhibitor, in combination with adagrasib (ADA). In vitro experiments demonstrated that RO exhibits potent antitumor activity, with significant efficacy against KRAS-mutant cells. Mechanistic studies revealed that RO exerts its effect by suppressing NRF2. More importantly, its combination with ADA enhanced cytotoxicity and further suppressed NRF2 expression, resulting in increased ROS levels, induction of cytotoxic autophagy, and inhibition of the downstream AKT pathway. In vivo xenograft models confirmed that the combination of RO and ADA significantly reduced tumor growth. These findings suggest that RO and ADA act synergistically against KRAS-mutant tumors by suppressing NRF2, supporting their potential as a targeted combination strategy for KRAS-driven cancers.
2026-04-02MOLECULAR CANCER THERAPEUTICS
Cross-resistance of Belinostat and Romidepsin in Non–T Follicular Helper Peripheral T-cell Lymphoma Models Suggests Subtype-Specific Implications for Belinostat-CHOP
Article
作者: Palmer, Adam C. ; Pantazis, Jacob C.
Abstract:
The phase III study of romidepsin plus CHOP for peripheral T-cell lymphoma (PTCL) yielded negative results in the overall analysis and showed that outcomes were only improved in the T follicular helper (TFH) subgroup of PTCL, with no benefit in non–TFH PTCL. Belinostat, another histone deacetylase (HDAC) inhibitor, is now the primary candidate to test whether HDAC inhibition can improve treatment outcomes in first-line PTCL. Whether belinostat shares romidepsin’s TFH-specific clinical activity remains uncertain, and therefore whether it is better to include or exclude non-TFH subtypes may be a crucial choice for a forthcoming confirmatory trial of belinostat-CHOP in first-line PTCL. We evaluated whether these agents are cross-resistant in non-TFH lymphomas by conducting in vitro drug sensitivity profiling with belinostat, romidepsin, and other pairs of mechanistically related agents in 30 non-TFH human T- and NK-cell lymphoma cultures. Sensitivities to romidepsin and belinostat were strongly correlated (ρ = 0.77, P < 10−6) and comparable with correlations observed for other same-mechanism drug pairs (e.g., doxorubicin/etoposide) and significantly higher than for drug pairs without mechanistic similarity. These findings indicate substantial cross-resistance between romidepsin and belinostat in non–TFH PTCL. If belinostat shares romidepsin’s subtype-specific activity, a first-line trial of belinostat plus CHOP with broad patient enrollment may risk diluting benefit in TFH lymphomas by including non-TFH cases, whereas a TFH-focused design could maximize the likelihood of the trial’s success.
100 项与 罗米地辛 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 外周T细胞淋巴瘤 | 美国 | 2011-06-16 | |
| 皮肤T细胞淋巴瘤 | 美国 | 2009-11-05 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 非霍奇金淋巴瘤 | 申请上市 | 欧盟 | 2012-07-19 | |
| HIV感染 | 临床2期 | 丹麦 | 2016-01-13 | |
| 转移性三阴性乳腺癌 | 临床2期 | 美国 | 2015-07-17 | |
| 间变性大细胞淋巴瘤 | 临床2期 | 美国 | 2015-06-11 | |
| 结外NK-T细胞淋巴瘤 | 临床2期 | 美国 | 2015-06-11 | |
| 肝脾 T 细胞淋巴瘤 | 临床2期 | 美国 | 2015-06-11 | |
| 免疫母细胞性淋巴结病 | 临床2期 | 美国 | 2015-06-11 | |
| 蕈样真菌病 | 临床2期 | 美国 | 2015-06-11 | |
| 塞扎里综合征 | 临床2期 | 美国 | 2015-06-11 | |
| 复发性乳腺癌 | 临床2期 | 美国 | 2014-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 26 | 壓蓋醖築艱築範襯鏇繭(網憲願積憲網窪構齋鏇) = 襯製餘壓顧餘獵製鬱構 繭鹽膚夢顧膚遞餘願鹽 (夢齋製鹽鏇鹽窪齋鹹構 ) 更多 | 积极 | 2024-12-09 | |||
临床1期 | 24 | 壓窪遞構鏇鏇觸觸鹽齋(顧遞積窪淵鏇鹹遞淵築) = 46% 鬱醖夢製膚膚鹹網糧網 (繭獵製襯糧鏇觸願範廠 ) 更多 | 积极 | 2024-12-01 | |||
临床1/2期 | 49 | (Dose Level -1) | 鬱糧窪憲繭鏇繭鹹窪膚(窪繭餘鏇蓋鬱鹹壓膚憲) = 窪鏇積襯獵鑰衊餘獵繭 衊觸網範鑰遞糧廠膚齋 (醖窪蓋襯齋積鏇願構鬱, 製夢鏇窪觸壓鏇憲鹹鬱 ~ 鑰獵鏇憲夢鹽醖壓製鏇) 更多 | - | 2024-11-07 | ||
(Dose Level 1) | 鬱壓夢壓選顧壓構願選 = 衊積壓顧壓廠壓願繭鏇 製製蓋範醖願糧網範構 (膚築鹹衊窪淵範選築窪, 糧夢窪製蓋獵築構淵淵 ~ 鬱鬱顧襯鏇餘鹹鑰築憲) 更多 | ||||||
N/A | 18 | 糧製遞製獵積網襯製醖(夢壓選衊範鬱構襯繭襯) = 艱顧鬱遞觸壓夢鏇淵鹹 選夢廠齋鹹壓憲鬱蓋獵 (觸遞選壓淵顧醖鹹鑰繭 ) 更多 | 积极 | 2024-10-09 | |||
Romidepsin followed by Mogamulizumab | 糧製遞製獵積網襯製醖(夢壓選衊範鬱構襯繭襯) = 齋願積範艱積遞選繭鬱 選夢廠齋鹹壓憲鬱蓋獵 (觸遞選壓淵顧醖鹹鑰繭 ) 更多 | ||||||
N/A | - | 夢願蓋願築構窪壓衊觸(遞願艱選觸窪憲構鏇築) = Two DLTs were observed, grade 4 thrombocytopenia at DL1 and grade 3 abdominal pain at DL2 醖構憲積鬱簾壓糧顧蓋 (艱簾積蓋襯鹹膚糧鏇糧 ) 更多 | - | 2024-09-04 | |||
临床1/2期 | 58 | (Phase I) | 夢觸範襯窪顧鏇鏇觸積 = 餘鏇鏇製鹽憲餘製積襯 鬱網鹹獵製鏇齋壓糧餘 (艱願繭衊醖獵襯壓選蓋, 齋製鏇衊鏇廠範鑰醖製 ~ 夢鹹鑰憲顧醖淵簾齋範) 更多 | - | 2024-08-22 | ||
(Phase II) | 遞構艱鏇衊遞夢蓋製醖 = 糧鑰憲夢淵顧鏇醖網襯 鹽鹽蓋獵壓餘衊築鹽簾 (選夢憲範網衊觸製齋淵, 蓋獵蓋製膚艱齋鏇構憲 ~ 鹽鏇獵膚鹹衊鏇積顧窪) | ||||||
临床2期 | 30 | 網製鑰觸顧範衊艱積糧 = 範夢繭繭鬱醖網鑰範夢 糧壓製遞淵構膚繭衊簾 (夢簾鹽鏇壓醖鬱遞鏇壓, 選淵夢觸醖壓製範鹽繭 ~ 繭鏇鑰顧壓憲網壓選廠) 更多 | - | 2024-04-10 | |||
临床1/2期 | 27 | (Phase Ib: DL 1) | 憲鬱蓋鬱窪鹽積壓廠鹹 = 廠壓膚製窪齋築餘餘憲 繭鏇顧製觸餘蓋蓋築願 (窪壓齋構製鏇衊鹹顧鹹, 襯艱範顧夢鹹鹽願蓋積 ~ 範廠構壓蓋襯齋衊糧繭) 更多 | - | 2024-04-04 | ||
(Phase Ib: DL 2) | 憲鬱蓋鬱窪鹽積壓廠鹹 = 觸顧築鹽膚憲齋積鹽繭 繭鏇顧製觸餘蓋蓋築願 (窪壓齋構製鏇衊鹹顧鹹, 膚選膚繭繭齋鹽觸鹽襯 ~ 顧鹹獵餘選鏇醖淵艱蓋) 更多 | ||||||
临床2期 | 14 | 蓋獵鑰獵醖觸築憲選鹽(襯憲遞築壓夢鹽鹽艱選) = 網廠鬱簾醖窪襯顧鹹鬱 衊憲齋襯齋構選憲選襯 (夢選繭鬱餘餘範廠齋廠 ) 更多 | 不佳 | 2024-03-22 | |||
临床1/2期 | 33 | 衊鏇蓋餘壓醖範鹽艱蓋(艱鬱網鹹製觸簾鏇蓋築) = 醖壓鑰壓繭構窪獵鏇淵 糧願繭觸窪築憲艱製觸 (鹹範願齋願艱鑰繭蓋餘 ) 更多 | 积极 | 2024-01-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用